Arrowhead to Present at Upcoming April Conferences

Home/Newsroom/

Arrowhead to Present at Upcoming...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical

company developing targeted RNAi therapeutics, today announced that the

company will make presentations at the following upcoming events.

The International Liver Congress™ 2016 (ILC 2016) – The Annual

Meeting of the European Association for the Study of the Liver –

Barcelona, Spain, April 13-17, 2016

April 14, 8:00 a.m. CEST – Zhao Xu, Ph.D., Arrowhead senior

scientist, and coauthors, will deliver a poster presentation titled, “Treatment

of chronically HBV-infected chimpanzees with RNA interference

therapeutic ARC-520 led to potent reduction of viral mRNA, DNA and

proteins without observed drug resistance” (abstract THU-213)

April 14, 8:00 a.m. CEST – Man-Fung Yuen, M.D., Ph.D., chair of

gastroenterology and hepatology, The University of Hong Kong, and deputy

chief of service, Queen Mary Hospital department of medicine, Hong Kong,

and coauthors, will deliver a poster presentation titled, “Differential

reductions in viral antigens expressed from cccDNA vs integrated DNA in

treatment naïve HBeAg positive and negative patients with chronic HBV

after RNA interference therapy with ARC-520” (abstract THU-193)

April 15, 8:00 a.m. CEST – Renae Walsh, Ph.D., senior scientist,

Victorian Infectious Diseases Reference Laboratory, and coauthors, will

deliver a poster presentation titled, “Predicting HBsAg clearance

responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg

epitope profile analysis” (abstract FRI-144)

American Association for Cancer Research Annual Meeting 2016 (AACR16) –

New Orleans, April 16-20, 2016

April 18, 1:00 p.m. CDT – So Wong, Ph.D., Arrowhead director of

oncology, and coauthors, will deliver a poster presentation titled, “Novel

HIF-2α targeted RNAi therapeutic for renal cell carcinoma” (abstract

2064)

Copies of presentation materials can be accessed by visiting the Events

section of the company’s website after each presentation is delivered.

About ARC-520

Arrowhead’s RNAi-based candidate ARC-520 is being investigated in the

treatment of chronic HBV infection. The small interfering RNAs (siRNAs)

in ARC-520 intervene at the mRNA level, upstream of the reverse

transcription process where current standard of care nucleotide and

nucleoside analogues act. Arrowhead is investigating ARC-520

specifically to determine if it can be used to achieve a functional

cure, which is an immune clearant state characterized by hepatitis B

s-antigen negative serum with or without seroconversion. Approximately

350-400 million people worldwide are chronically infected with the

hepatitis B virus, which can lead to cirrhosis of the liver and is

responsible for 80% of primary liver cancers globally. Arrowhead is

currently conducting Phase 2b multiple dose and combination studies in

chronic HBV patients. In clinical studies to date, the most common

reported adverse events in all subjects completing treatment were upper

respiratory infection and headache.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing

targeted RNAi therapeutics. The company is leveraging its proprietary

Dynamic Polyconjugate™ delivery platform to develop targeted

drugs based on the RNA interference mechanism that efficiently silences

disease-causing genes. Arrowhead’s pipeline includes ARC-520 and ARC-521

for chronic hepatitis B virus, ARC-AAT for liver disease associated with

alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and

thromboembolic diseases, ARC-LPA for cardiovascular disease, and

ARC-HIF2 for renal cell carcinoma.

For more information please visit http://www.arrowheadresearch.com,

or follow us on Twitter @ArrowRes.

To be added to the Company’s email list and receive news directly,

please visit http://ir.arrowheadresearch.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. These statements are based upon our

current expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including our ability to finance our operations, the

future success of our scientific studies, our ability to successfully

develop drug candidates, the timing for starting and completing clinical

trials, rapid technological change in our markets, and the enforcement

of our intellectual property rights. Arrowhead Research Corporation’s

most recent Annual Report on Form 10-K and subsequent Quarterly Reports

on Form 10-Q discuss some of the important risk factors that may affect

our business, results of operations and financial condition. We assume

no obligation to update or revise forward-looking statements to reflect

new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research

Corporation.

Source: Arrowhead Research Corporation

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor

Relations:
The Trout Group
Chad Rubin
646-378-2947
ir@arrowres.com
or
Media:
Russo

Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com

Source: Arrowhead Research Corporation

News Provided by Acquire Media